CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer
Shots:
- The NMPA has cleared an IND application for CT041, an autologous CAR T-cell product for the postoperative adjuvant therapy against the protein Claudin18.2 of CLDN18.2+ pancreatic cancer (PC)
- CT041 showed promising efficacy in treating pancreatic cancer in previous clinical trials. The company continues to explore the use of CAR T-cells in the earlier line treatment of multiple cancer types
- CT041 received ODD from the US FDA for the treatment of GC/GEJ cancer and Orphan Medicinal Product designation from the EMA for advanced gastric cancer. Additionally, the P-II study of CT041 is expected to be initiated in H1’23 in the US
Ref: prnewswire | Image: CARsgen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
